University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 — Philadelphia, Pennsylvania

University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 is a clinical research site located in Philadelphia, Pennsylvania, United States 19104.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 has participated in 1 clinical trials.

Therapeutic areas: Multiple Myeloma.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102?

University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 conducted?

University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 has 1 clinical trials on record. Their work covers Multiple Myeloma.

Is University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 accredited by Crixeo Health?

University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.